WELL Health Reports Record Quarterly Revenue and Record Net Income for a first quarter in Q1-2024 and Increases Both Revenue and Adjusted EBITDA Guidance for 2024
WELL's Canadian business grew its Adjusted EBITDA in Q1- 2024 by 19% to $14.6 million on a YoY basis.
- WELL's Canadian business grew its Adjusted EBITDA in Q1- 2024 by 19% to $14.6 million on a YoY basis.
- WELL is pleased to provide guidance of an improvement of FCFA2S of more than $55M in 2024, a 30% increase from $42.4 million in 2023.
- WELL increases its guidance range for 2024 annual revenue of between $960 million to $980 million, while guiding to upper range of its previous Adjusted EBITDA guidance of $125 million to $130 million.
- First Quarter 2024 Financial Highlights:
WELL achieved record quarterly revenue of $231.6 million in Q1-2024, an increase of 37% as compared to revenue of $169.4 million generated in Q1-2023.